{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-019706","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.345062+00:00","generated_at":"2026-05-17T02:09:17.517851+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cocrystal Pharma receives ~$500K NIH SBIR award for influenza antiviral program","bullets":["Award from NIH/NIAID to support development of novel oral broad-spectrum antiviral for influenza A and B.","Approximately $500,000 in non-dilutive funding; Phase I award to assess scientific and commercial potential.","Funds will be used to characterize lead candidate molecules inhibiting the influenza polymerase complex.","Successful Phase I completion may qualify Cocrystal to apply for a larger Phase II award.","Company continues to pursue additional non-dilutive government and military funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-019706","json":"https://secwatch.observer/filing/0001493152-25-019706.json","markdown":"https://secwatch.observer/filing/0001493152-25-019706.md","text":"https://secwatch.observer/filing/0001493152-25-019706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225019706/0001493152-25-019706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315225019706/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:09:17.517851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}